ENTXEntera Bio
About Entera Bio
Entera Bio (NASDAQ:ENTX) is a biotechnology firm focused on developing orally delivered large molecule therapeutics for use in areas with significant unmet medical need. Specializing in the oral delivery technology, Entera Bio's projects primarily target osteoporosis, hypoparathyroidism, and other serious illnesses that currently depend on injections or infusions for treatment. The company's objective is to advance these programs through clinical development, aiming to offer patients more convenient and less invasive treatment options. Entera's innovative approach could transform the way large molecule therapeutics are administered, offering a potentially groundbreaking advancement in patient care.
What is ENTX known for?
Snapshot
Public US
Ownership
2009
Year founded
18
Employees
Jerusalem, Israel
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
State of Israel
Products and/or services of Entera Bio
- Developing EB613, an oral human parathyroid hormone for osteoporosis, aiming to improve bone density and reduce fracture risk.
- EB612, an oral treatment targeting hypoparathyroidism, designed to normalize blood calcium levels and minimize urinary calcium excretion.
- Collaboration on developing oral formulations of large molecule therapeutics, utilizing a proprietary drug delivery platform to enhance bioavailability and patient compliance.
- Research on oral peptide delivery technologies to transform injectable treatments into oral formulations, focusing on improving patient experience and treatment efficacy.
- Initiatives in developing oral formulations for various biologics, broadening treatment options for diseases requiring biologic therapies by bypassing the need for injections.
- Engagement in partnerships with pharmaceutical companies to expand the application of its drug delivery technology across different therapeutic areas and compounds.
Entera Bio executive team
- Ms. Miranda J. Toledano M.B.A.CEO & Director
- Ms. Dana Yaacov-Garbeli CPAChief Financial Officer
- Dr. Hillel Galitzer M.B.A., Ph.D.Chief Operating Officer
- Dr. Gregory Burshtein Ph.D.Chief of Research & Development
- Dr. Rachel B. WagmanChief Clinical Advisor
- Ms. Cherin SmithExecutive VP & Head of Clinical Operations
- Dr. Constantin Itin Ph.D., R.Ph.Head of Biopharmaceutics & Bioanalytics